BioVie Inc. — FY2017 Form 10-K
Reporting period: Fiscal year ended June 30, 2017; comparative figures are for the year ended June 30, 2016. Although the request metadata refers to 2016 Q4, the filing covers FY2017. BioVie is a clinical-stage biotechnology company focused on BIV201, an investigational terlipressin therapy for ascites caused by liver cirrhosis. It reported no product revenue.
Financial results and liquidity
| Metric | FY2017 | FY2016 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $1,553,614 | $432,028 |
| Research and development | $466,354 | $37,901 |
| Operating loss | $1,553,614 | $432,028 |
| Other income, net | $222,942 | $105 |
| Net loss | $1,330,672 | $431,923 |
| Net cash used in operations | $623,615 | $153,631 |
With no revenue or cost of goods sold, gross margin is not meaningful. Operating expenses rose substantially, particularly R&D, amortization, and professional fees. Net loss increased by about $899,000, partly offset by noncash/other income related principally to forgiveness of salary debt.
At June 30, 2017, reported cash was $5,140 on the balance sheet (the cash-flow statement reports $5,141); current assets were $5,140 and current liabilities $630,973. Total liabilities were $1,206,891, including $35,000 of zero-interest related-party loans and $575,918 of long-term accrued expenses and payroll. Stockholders’ equity was $1,157,318. No material off-balance-sheet arrangements were reported. The auditor’s opinion was unqualified but included a going-concern emphasis; the filing says substantial doubt exists about the company’s ability to continue operating.
Business progress, changes, and outlook
- FDA authorization to begin a Phase 2a U.S. trial for BIV201 was received in March 2017; an IRB approved the trial at McGuire Research Institute in June. The filing describes plans to begin dosing in mid-2017, but does not report trial results.
- BIV201 received U.S. Orphan Drug designation, and the company reported issuance of a U.S. patent covering its use for ascites with ambulatory-pump administration. The company also described patent filings in Japan and Europe.
- BioVie acquired LAT Pharma and the BIV201 development program in April 2016. Its prior nanoantibiotics program was inactive as the company focused on BIV201.
- Management estimated next-12-month spending of $3 million for R&D, $500,000 for corporate overhead, and $500,000 for staffing. It stated that approximately $4 million–$5 million of additional net financing was needed, and that existing cash would not fund planned operations through June 30, 2018.
- A January 2017 agreement gives Aspire Capital the potential to purchase up to $12 million of common stock over 30 months, subject to the agreement’s conditions and the company’s sale notices. The filing does not establish that this amount will be raised. Management also cited potential equity or debt financing, licensing, partnerships, or other transactions; without funding, it may delay or reduce development or cease operations.
Risks, contingencies, and unusual items
- BIV201 remains investigational; safety, efficacy, regulatory approval, successful commercialization, and market adoption are uncertain. Clinical development depends on adequate funding.
- The company has no approved products, no revenue, limited operating history, and expects continued losses. It reported only a small workforce and reliance on consultants and third parties.
- Management and the auditor identified substantial doubt about going concern. The financial statements contain no adjustments that might result if the company cannot continue as a going concern.
- Material weaknesses included a lack of formalized financial controls and segregation of duties, and no independent audit committee chair. Management concluded disclosure controls and internal control over financial reporting were ineffective as of June 30, 2017.
- Related-party and deferred obligations warrant attention: CEO Jonathan Adams provided a $35,000 demand loan; various salary and consulting amounts were deferred to December 31, 2019, generally without interest if paid by then, with 5% interest thereafter. The filing reports forgiveness of half of Elliot Ehrlich’s salary debt as other income.
- The company issued shares and warrants during the year and had 91,925,000 common shares outstanding at June 30, 2017. Further fundraising could dilute existing holders; OTC trading is described as limited and volatile. No cash dividends are anticipated.
Key facts for investors to verify
- Cash is reported as both $5,140 and $5,141; verify the correct year-end cash balance and reconciliation.
- Confirm the actual Phase 2a trial start, enrollment, dosing, and any results after the filing date.
- Assess cash runway and whether the Aspire Capital facility or other financing produced usable proceeds; the stated $12 million commitment is not equivalent to committed cash funding.
- Reconcile related-party and deferred liabilities, including the amount forgiven and the corresponding other-income figure.
- Review remediation of the disclosed material weaknesses and the impact of future share and warrant issuance on dilution.